This session addresses the unique challenges posed by complex coronary anatomy in STEMI patients. Through detailed case discussions, it highlights management of anomalous culprit origins, multifaceted infarcts, rare presentations, and urgent primary PCI strategies in anatomically complex scenarios. The session emphasizes adaptive techniques to navigate unexpected...

This session investigates complications encountered during primary percutaneous coronary interventions (PCI). It covers management of no-reflow phenomena, innovative guide extension catheter aspiration techniques for thrombus-rich STEMI, challenges when balloon crossing fails, vein graft PCI pitfalls, and complex concurrent ischemic events involving myocardial infarction and limb ischemia....

This session provides an in-depth exploration of regulatory and reimbursement pathways critical for MedTech innovators. It covers the transition challenges from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR), sharing lessons learned and success stories. The session also addresses reimbursement frameworks in the...

This session examines critical success factors for MedTech start-ups through real-world examples, discussing challenges, investment dynamics, and the pivotal role of the Chief Medical Officer and investor syndicates in fostering sustainable growth.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.